OPTIMISING RURAL MUSCULOSKELETAL HEALTH
Adnan Asger Ali, PhD candidate
The University of Sydney &
Director & Principal Physiotherapist
Accelerate Physiotherapy, Canberra, Australia &
Chair of Business and Finance Committee,
International Federation of Manual and Musculoskeletal Physical Therapists Incorporated (IFOMPT) &
Chair, National Musculoskeletal Committee,
Australian Physiotherapy Association
RESEARCHER PROFILE
Filmed in Canberra, Australia | September 2025
Adnan Asger Ali is a Director of Accelerate Physiotherapy and PhD candidate at The University of Sydney, where he is researching implementation strategies for musculoskeletal care pathways in rural Australia as part of the PACE-RURAL project.
Graduating from The University of Canberra, Adnan completed a Masters in Musculoskeletal Physiotherapy at La Trobe University and a Masters in Pain Management at The University of Sydney. He is one of few physiotherapists in Australia holding dual APA titles as both Musculoskeletal and Pain Physiotherapist.
A passionate advocate for physiotherapy, Adnan serves as Chair of the Australian Physiotherapy Association’s National Musculoskeletal Committee and sits on the Capital Health Network’s Clinical Council. His commitment to clinical excellence was recognised when he received Physiotherapist of the Year at the 2023 Allied Health Awards.
Adnan has extensive sports physiotherapy experience, currently working with Tennis Australia treating professional players on international tours and at The Australian Open. Through his research and clinical practice, he is dedicated to improving access to evidence-based musculoskeletal care for all Australians.
Source: Supplied
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
New treatments for patients with mental illness
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
-
Interventions for improving outcomes of children who are deaf or hard of hearing
Professor Teresa Ching is a Conjoint Professor at NextSense Institute and Macquarie University, and an Honorary Professor at the University of Queensland in Australia. Her current research focuses on devising culturally sensitive practices in early detection and intervention to maximise children’s outcomes. Working with international colleagues, her current research is also directed towards developing global guidelines and recommendations for hearing screening beyond the newborn period, so that all children can benefit from early detection and intervention. The ultimate goal is to attain equity of care and outcomes for all children with hearing difficulties.
